Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd has submitted a certificate to BSE stating that Regulation 57(5) does not apply to the company for the quarter ended 31 March 2025. The company confirmed it has no non-convertible securities outstanding on which interest, dividend, or principal payments are due during the quarter. The filing was signed by the Managing Director and is a routine quarterly compliance submission.
This is a routine regulatory filing with no impact on shareholders or the stock price. It simply confirms the company does not have non-convertible securities requiring periodic disclosures under this regulation.